马来酸曲美布汀联合抗抑郁药物治疗肠易激综合征的临床研究

摘要

ObjectiveTo investigate the clinical efficacy of antidepressants combined with trimebutine maleate deanxit on treating irritable bowel syndrome(IBS).Methods Selecting 82 IBS patients and stochastically dividing into joint group and control group, each group with 41 cases. The control group was treated only by trimebutine maleate and the joint group was treated by trimebutine maleate deanxit on the basis of control group. Compare the two groups’ clinical efifcacy and mental status changes.Results The cure rate and general efifciency of the joint group were obviously higher than the control group, their difference has statistic signiifcance(P<0.05); the scores contrast of the two groups patients’ SDS and HAMA before the treatment has no statistic signiifcance(P>0.05); the scores contrast of the joint group’s SDS and HAMA after the treatment were both lower than control group(P<0.05), which has statistic signiifcance.Conclusion In IBS clinical treatment, trimebutine maleate combined with antidepressants can effectively relieve the patient's depression and improve the gastrointestinal symptoms, which should be widely applied.%目的：探讨马来酸曲美布汀联合抗抑郁药物黛力新治疗肠易激综合征（IBS）的临床疗效。方法选取我院收治的82例IBS患者作为研究对象，并随机分为联合组和对照组各41例，对照组患者单用马来酸曲美布汀进行治疗，联合组在此基础上加用抗抑郁药物黛力新，对比两组患者的临床疗效及心理状态变化。结果联合组患者的治愈率、总有效率均显著高于对照组，差异具有统计学意义（P＜0.05）；两组患者治疗前的SDS、HAMA评分比较，差异均不具有统计学意义（P＞0.05）；联合组治疗后的SDS、HAMA评分均显著低于对照组，差异均具有统计学意义（P＜0.05）。结论在IBS的临床治疗中，联合应用马来酸曲美布汀和抗抑郁药物，可有效缓解患者的抑郁情绪，改善消化道症状，疗效确切，值得推广应用。